Don't Judge Exact Sciences on Technicals Alone - Check Its Fundamentals!

By Tamara Parker • Friday, August 25 11:20 • Permanent Link

Mid-cap Health Care company Exact Sciences has moved 1.0% so far today on a volume of 232,636, compared to its average of 1,612,174. In contrast, the S&P 500 index moved -0.0%.

Exact Sciences trades -25.73% away from its average analyst target price of $108.36 per share. The 17 analysts following the stock have set target prices ranging from $80.2 to $130.0, and on average have given Exact Sciences a rating of buy.

Anyone interested in buying EXAS should be aware of the facts below:

Exact Sciences has moved 118.0% over the last year, and the S&P 500 logged a change of 9.0%
Based on its trailing earnings per share of -2.29, Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -35.1 while the S&P 500 average is 15.97
EXAS has a forward P/E ratio of -74.5 based on its forward 12 month price to earnings (EPS) of $-1.08 per share
The company has a price to earnings growth (PEG) ratio of -0.44 — a number near or below 1 signifying that Exact Sciences is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 4.75 compared to its sector average of 4.16
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
Based in Madison, the company has 6,300 full time employees and a market cap of $14.54 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.